Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

3,724JPY
2:00am EDT
Change (% chg)

¥-42 (-1.12%)
Prev Close
¥3,766
Open
¥3,797
Day's High
¥3,836
Day's Low
¥3,721
Volume
1,499,000
Avg. Vol
2,414,265
52-wk High
¥4,241
52-wk Low
¥2,284

Chart for

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.84
Market Cap(Mil.): ¥2,670,137.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 1.86

Financials

  4568.T Industry Sector
P/E (TTM): 66.04 30.61 33.50
EPS (TTM): 57.03 -- --
ROI: 1.99 13.57 13.17
ROE: 3.12 15.25 14.98

BRIEF-‍Daiichi Sankyo And Darwinhealth Enter Exclusive Research Collaboration For Novel Cancer Target Initiative​

* ‍DAIICHI SANKYO AND DARWINHEALTH ENTER EXCLUSIVE RESEARCH COLLABORATION FOR NOVEL CANCER TARGET INITIATIVE​

Apr 04 2018

BRIEF-Daiichi Sankyo completes share repurchase

* Says it accumulatively repurchased 15.7 million shares for 50 billion yen in total as of March 22

Mar 22 2018

BRIEF-Fortis Healthcare Gets Court Order Relating To Daiichi Sankyo Co Case

* GETS COURT ORDER RELATING TO DAIICHI SANKYO COMPANY LIMITED CASE

Mar 22 2018

BRIEF-Daiichi Sankyo Initiates Phase 2 Study Of DS-8201

* DAIICHI SANKYO INITIATES PHASE 2 STUDY OF DS-8201 IN PATIENTS WITH HER2-EXPRESSING ADVANCED COLORECTAL CANCER Source text for Eikon: Further company coverage:

Mar 07 2018

BRIEF-Medrx signs joint development contract with DAIICHI SANKYO

* Says it signed a joint development contract with DAIICHI SANKYO COMPANY, LIMITED, regarding development candidates using Nano-sized Colloid Transdermal System owned by the company

Feb 28 2018

BRIEF-Daiichi Sankyo's Regulatory Submission Triggers $20 Mln Milestone Payment To Exelixis​

* CO ‍ANNOUNCES COLLABORATOR DAIICHI SANKYO'S SUBMISSION OF REGULATORY FILING FOR ESAXERENONE (CS-3150) IN JAPAN​

Feb 26 2018

BRIEF-Daiichi Sankyo Initiates Phase 1 Study Of DS-1062 In Patients With Advanced Non-Small Cell Lung Cancer

* DAIICHI SANKYO INITIATES PHASE 1 STUDY OF DS-1062 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER Source text for Eikon: Further company coverage:

Feb 22 2018

Fortis shares jump as troubled Singh brothers quit as directors

MUMBAI, Feb 9 Shares in Fortis Healthcare Ltd jumped as much as 24 percent on Friday after main shareholders Malvinder Mohan Singh and Shivinder Mohan Singh resigned from the board saying it was in the interests of the company because of legal troubles they were facing.

Feb 09 2018

BRIEF-Vernalis has entered into drug discovery collaboration with Daiichi Sankyo

* VERNALIS SAYS ‍HAS ENTERED INTO DRUG DISCOVERY COLLABORATION WITH DAIICHI SANKYO COMPANY, LIMITED UTILIZING VERNALIS' DRUG DISCOVERY PLATFORM​

Dec 13 2017

BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer

* DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER Source text for Eikon: Further company coverage:

Dec 12 2017

Earnings vs. Estimates